In addition, our studies have revealed that the triple combination therapy is capable of offering improved antitumor efficacy in the TC-1 tumor mouse model, which is related to an increase in antigen-specific lymphocyte proliferation, CD8 + cytotoxicity, and IFN-γ, IL-4, and IL-10 induction. This evidence concerns the gene CD8A and neoplasm.